

Review

Histopathology of Thyroid Tumors. An Overview

Chrisoula D. Scopa

Dept. of Pathology, University of Patras, School of Health Sciences, Faculty of Medicine, Patras, Greece

INTRODUCTION

Thyroid cancer accounts for approximately 1% of total cancer cases in developed countries. It affects all age groups, although it is rare in children. Thyroid tumors are more frequent in women than in men. Despite their relative rarity they exhibit a wide range of morphological patterns and biological behavior which may explain the great interest in these neoplasms of both pathologists and clinicians.

Another issue of considerable interest is the molecular abnormalities involved in thyroid tumor pathology. In this review, following the histologic classification of thyroid neoplasms with their histologic and cytologic variants, a brief discussion of some of the most relevant molecular alterations recently described will be undertaken.

A. HISTOPATHOLOGY

The thyroid gland contains two major types of epithelial cells: the follicular cells, which convert iodine into thyroxine and triiodothyronine, and the parafollicular or C-cells, which secrete calcitonin. Thyroid tumors can originate from these very different kinds

of cells or from nonepithelial stromal elements, and architectural, cytologic and histogenetic features have been taken into consideration for neoplasms classification. According to the World Health Organization (WHO)¹ primary thyroid tumors are classified as epithelial and nonepithelial, benign or malignant, with a separate category for lymphomas and miscellaneous neoplasms (Table 1). A slightly different classification scheme has been adopted by the Armed Forces Institute of Pathology (AFIP)², giving priority to the cell of origin and incorporating, in each cell type, special tumor types and subtypes designated as “variants” (Table 2). This review is based on the AFIP classification.

The traditional classification of thyroid cancer as well differentiated carcinomas (papillary and follicular) characterized by relatively good prognosis, or poorly differentiated carcinomas (follicular, anaplastic) associated with aggressive behavior, metastases and death, is no longer applicable since certain morphologic variants of papillary carcinoma are associated with poor prognosis. In addition, the existence of true mixed forms of papillary and follicular cancers has been disproved, while new entities such as “mixed follicular-parafollicular carcinoma” have emerged³.

The criteria for the recognition of follicular and papillary carcinomas have changed in recent years but both denominations have been retained. Papillae no longer seem to be necessary for the diagnosis of papillary carcinoma, and cytologic features such as oncocyctic, clear cell, squamous and mucinous changes have resulted in the designation of special tumor types and subtypes. The practical importance of these special types resides in differential diagnosis rather than their biological behavior².

Key words: Thyroid, Thyroid histopathology, Tumors, Oncogenes

Address correspondence and requests for reprints to:
Chrisoula D. Scopa, M.D., P.O. Box 1174, 261 10 Patras,
Greece, Tel: +30-2610- 990 038, Fax: +30-2610- 990 775,
e-mail: cdscopa@med.upatras.gr
Received 04-02-04, Revised 05-03-04, Accepted 10-03-04

Table 1. Histologic Classification of Thyroid Tumors (WHO)¹

I. Epithelial Tumors
A. Benign
1. Follicular adenoma
2. Others
B. Malignant
1. Follicular carcinoma
2. Papillary carcinoma
3. Medullary carcinoma
4. Undifferentiated (anaplastic) carcinoma
5. Others
II. Nonepithelial Tumors
A. Benign
B. Malignant
III. Malignant lymphomas
IV. Miscellaneous
V. Secondary tumors
VI. Unclassified tumors
VII. Tumor-like lesions

A.1. TUMORS OF FOLLICULAR CELLS AND THEIR VARIANTS**A.1.1. Follicular Adenoma**

Follicular adenoma is defined as a benign encapsulated tumor with follicular cell differentiation showing a uniform pattern throughout the confine nodule (Figure 1A). The fibrous capsule varies in thickness, but is usually thin. Follicular adenomas are solitary tumors with a solid, homogeneous cut surface, but hemorrhage and cystic degeneration are not uncommon. Their size is highly variable, ranging from 1 cm to over 10 cm. On the basis of microscopic features, several variants have been described, including oncocytic adenoma (Hürthle cell adenoma), adenoma with clear cell change, atypical adenoma, hyalinizing trabecular adenoma, adenoma with bizarre nuclei and rare types such as adenoma with adipose (adenolipoma) or cartilagenous (adenochondroma) metaplasia². Recent studies suggest that hyalinizing trabecular adenoma, also described as hyalinizing trabecular tumor

Table 2. Classification of Thyroid Tumors (AFIP)²**PRIMARY TUMORS**

1. Epithelial tumors
 - A. Tumors of follicular cells
 - Benign: Follicular adenoma (conventional, variants*)
 - Malignant: carcinoma differentiated
 - follicular carcinoma
 - papillary carcinoma (conventional, variants**)
 - poorly differentiated (insular carcinoma, others)
 - undifferentiated or anaplastic
 - B. Tumors of C-cells (and related neuroendocrine cells)
 - medullary carcinoma
 - others
 - C. Tumors of follicular and C-cells
 - mixed medullary-follicular carcinoma
2. Sarcomas
3. Malignant lymphoma (and related hematopoietic neoplasms)
4. Miscellaneous neoplasms

SECONDARY TUMORS**TUMOR-LIKE LESIONS**

* oncocytic, clear cell changes, atypical adenoma, hyalinizing trabecular, with bizarre nuclei

** microcarcinoma, encapsulated, follicular, tall/columnar cell, diffuse sclerosing, solid/trabecular

and “paraganglioma-like adenoma of the thyroid”, may be related to papillary carcinoma at the molecular level^{4,5}, while others propose a multidirectional differentiation from pluripotent primitive cells⁶. Some of these controversial issues are challenged by Lloyd⁷ who concludes that additional studies are needed to clearly define this entity. Until then, it would seem appropriate to regard and treat hyalinizing trabecular adenoma as a benign neoplasm². “Toxic” adenoma is a clinical rather than a pathologic entity, defining only those hyperfunctioning lesions in which clinical manifestations occur, and not any “hot” adenoma².

A.1.2. Follicular Carcinoma

Most authors agree that only follicular tumors that exhibit vascular and/or capsular invasion should be regarded as follicular carcinomas⁸. Depending on the degree of their invasiveness, follicular carcinomas have been divided into two major categories: minimally invasive or encapsulated (the most common), and widely invasive. The frequency of follicular carcinoma among thyroid malignancies ranges from 5-10% in non-iodine-deficient areas to 30-40% in iodine-deficient areas².

Macroscopically, follicular carcinomas do not differ appreciably from follicular adenomas. The fibrous capsule surrounding the tumor tends to be thicker and more irregular than in adenomas². Minimally invasive follicular carcinoma is an encapsulated tumor showing capsular and/or vascular invasion only on microscopic evaluation, while the widely invasive neoplasm shows lack of complete encapsulation, extensive areas of invasion to the adjacent thyroid tissue and/or widespread blood vessels infiltration^{2,8}.

Immunohistochemistry, morphometry, ploidy analysis, cytogenetic and oncogene markers have failed to provide reliable information concerning the distinction between follicular carcinoma and follicular adenoma. The current diagnostic criteria for malignancy are still the histologic assessment of true capsular infiltration (the tumor must penetrate the entire thickness of the capsule) and/or invasion of blood vessels in or beyond the capsule (Figure 1B)^{2,8-10}. It is apparent that minimally invasive follicular tumors cannot be accurately diagnosed by fine needle aspiration (FNA) cytology since the crucial diagnostic criteria are missing^{2,9,11}. Similar problems exist in evaluating such lesions by frozen section^{2,11,12}.

Malignant thyroid tumors composed exclusively or predominately (over 75%) of oncocytes (Hürthle cell tumors) share some similarities with follicular carcinomas as regards the clinical presentation, the architectural features and the degree of invasiveness, and therefore should be considered as a variant of follicular carcinoma^{2,8,9}. However, some authors have suggested that the morphologic features and natural history of these tumors are distinctive enough that they be considered as a separate entity^{13,14}.

A.1.3. Papillary Carcinoma

Papillary carcinoma is the most common type of thyroid cancer, comprising approximately 80% of all primary thyroid malignancies¹⁵. Classical or non-otherwise specified (NOS) papillary carcinoma is characterized by the formation of papillae and a set of distinctive nuclear features (optically clear appearance, overlapping, pseudoinclusions and nuclear grooves) (Figure 1C, 1D)^{2,16-18}. The size of papillary carcinoma is extremely variable with a mean diameter of 2-3 cm². A clinically detected tumor is usually confined to the thyroid, is presented as a fairly well circumscribed or infiltrative neoplasm and has an indolent course. Its mode of spread is most commonly via lymphatics within the thyroid leading to “multifocal” disease and to cervical node metastases^{2,9}. Indeed, 50% or more of papillary carcinomas have nodal metastases at initial diagnosis¹⁹.

There are several histologic variants of papillary carcinoma, some of which are associated with a more guarded prognosis (Table 3)¹⁰.

A.1.3.a. Variants of papillary carcinoma

a.1. Papillary microcarcinoma: The term refers to papillary carcinomas measuring 1cm or less in diameter and replaces the older designation of occult sclerosing carcinoma, also known as nonencapsulated sclerosing tumor and occult papillary carcinoma². Re-

Table 3. Variants of Papillary Carcinoma and their Prognosis¹⁰

Good	Variable	Guarded
Microcarcinoma	Oxyphilic cell	Diffuse sclerosing
Encapsulated	Follicular	Tall/columnar cell
Macrofollicular	Solid sclerosing	Diffuse follicular
	Solid/trabecular	
	With nodular	
	fasciitis-like stroma	

cently, at the 12th Annual Cancer Meeting held at Porto, Portugal, a consensus was reached by a group of experts to rename this entity as papillary microtumor²⁰. Papillary microcarcinomas are frequently detected as incidental findings in autopsy or in surgical specimens and are associated with an excellent prognosis despite occasional regional lymph node metastases. The reported incidence in autopsy material has ranged from 4% to 35.6%^{2,21-23}.

a.2. Encapsulated variant: The tumor is totally surrounded by a fibrous capsule which may be intact or focally infiltrated by the tumor. These tumors have an exceptionally good prognosis and, although some lesions have shown lymph node involvement, distant metastases or death due to tumor are practically nonexistent²⁴.

a.3. Follicular variant: Papillary carcinomas having an exclusive or almost exclusive follicular pattern are designated as a follicular variant of papillary carcinoma. The biologic behavior of this variant is analogous to that of conventional papillary carcinoma. The metastases may have a mixed papillary and follicular formation. A diffuse or widely invasive form of the follicular variant and macrofollicular variant of papillary carcinoma have also been described^{25,26}.

a.4. Tall and columnar cell variant: The main histologic feature of the tall cell variant of papillary carcinoma is the presence of “tall” cells (the height being twice the width), with an intense eosinophilic cytoplasm, lining well-developed papillae (Figure 1E). In the columnar cell variant, there is a marked nuclear stratification and the cytoplasm is clear, sometimes with subnuclear vacuolization²⁹. Both the tall cell and columnar cell variant are said to be more aggressive than classical papillary carcinomas^{27,28}. However, recent studies suggest that the clinical behavior of these rare types of papillary carcinoma depends on tumor size, extrathyroidal invasion and distant metastases^{29,30}.

a.5. Diffuse sclerosing variant: This is an unusual form of papillary carcinoma first described by Vickery et al²², who noticed that it more frequently affects children and is associated with a poor prognosis. This tumor is characterized by diffuse involvement of one or two lobes and clinically may be misdiagnosed as Hashimoto’s thyroiditis². Its hallmark, microscopically, is the presence of widespread intrathyroid lymphatic permeation by numerous neoplastic micropapillae.

a.6. Other variants: Variants such as solid variant, clear cell and oxyphilic variant, papillary carcinoma with lipomatous stroma, Warthin’s-like tumor or with nodular fasciitis-like stroma and cribriform papillary carcinoma have been reported, but they are too few in number for an adequate assessment of their prognostic implication^{2,15,31}. The term solid and/or trabecular variant is used when a NOS papillary carcinoma has a solid and/or trabecular pattern throughout the tumor².

A.1.4. Poorly Differentiated Carcinoma

Poorly differentiated thyroid carcinoma represents a heterogeneous group of malignant neoplasms, with various histologic patterns of growth and different biologic behavior, that lie somewhere between well-differentiated and undifferentiated carcinomas^{6,31-33}. The heterogeneity of these tumors reflects the different terms used to describe and diagnose this entity, including solid, trabecular, insular, poorly differentiated, intermediate type, less well-differentiated and follicular carcinoma with insular component^{2,32-35}.

Macroscopically, poorly differentiated carcinomas usually present as large (>5 cm in diameter), solid, unencapsulated, nodular or multinodular, grey-white tumors that tend to invade perithyroidal tissues^{2,15,33}. Microscopically, the majority of these tumors show a trabecular, solid or insular growth pattern¹⁰. A combination of other histologic features such as follicles, columnar cell carcinoma, papillary, follicular and Hürthle cell carcinoma foci have been found^{2,31-33}.

Recent studies on molecular and genetic features of poorly differentiated carcinomas provide evidence that there is a link between these tumors and the papillary thyroid carcinoma, and they support the concept that poorly differentiated carcinoma represents an immediate step in the progression from well-differentiated to undifferentiated carcinomas^{36,37}. However, a divergent histogenesis must also be considered since poorly differentiated carcinomas exhibit, in addition to the usual thyroglobulin immunoreactivity, focal immunoreactivity to neuroendocrine markers, such as calcitonin, neurotensin and somatostatin^{33,35,38}.

Apart from tumor stage, clinicopathologic features such as tumor necrosis, mitotic count (>3/10HPF) and the age (>45 years) of the patient, have been reported as being significantly associated with the clinically aggressive behavior of these tumors^{32,33}.

A.1.5. Undifferentiated (Anaplastic) Carcinoma

Undifferentiated thyroid carcinomas account for 5-10% of all primary malignant tumors of the thyroid². These tumors, usually present in elderly patients (mean age 60-65 years), are rapidly growing, with massive local invasion and early distant metastases, most frequently to lung, adrenals and bone^{2,9}.

Undifferentiated thyroid carcinoma exhibits a wide spectrum of morphologic types, singly or in combination. The three major patterns of growth are squamoid (morphologic similarity to nonkeratinizing squamous cell carcinoma), spindle cell (sarcoma-like growth) and giant cell (numerous osteoclast-like multinucleated giant cells, resembling giant cell tumor of the bone or soft tissues) (Figure 1F). Features common to all three types are high mitotic activity, extensive necrosis and a marked degree of invasiveness within the gland as well as to the extrathyroidal structures^{2,9}.

Areas of pre-existing well-differentiated thyroid tumor (more often follicular or papillary carcinoma) can be seen in many, if not most, undifferentiated carcinomas. On the other hand, the undifferentiated tumor may develop months or years after the removal of a well-differentiated thyroid neoplasm. These findings support the hypothesis that undifferentiated thyroid tumors arise from pre-existing well-differentiated thyroid carcinomas^{2,39}.

A.2. TUMORS OF C-CELLS AND THEIR VARIANTS

A.2.1. Medullary Carcinoma

Medullary thyroid carcinoma is a malignant tumor of the thyroid which shows evidence of C-cell differentiation and usually contains calcitonin (Figure 1G)². It accounts for up to 10% of all malignant thyroid tumors^{2,15}. The variants of medullary carcinoma are: glandular (composed in part of tubular or follicular structures and may resemble follicular carcinoma), papillary (exhibiting true papillary pattern of growth), small cell (resembling the intermediate variant of small cell carcinoma of the lung), and giant cell (occasionally present or focal areas with giant cell formation). Less common are the clear cell, melanotic (pigmented), oncocyctic (oxyphilic), squamous, amphicrine (calcitonin and mucin-producing cells) and paraganglioma-like variants^{2,40}.

A.2.2. Mixed follicular–parafollicular Carcinoma

Mixed medullary and follicular carcinoma are rare neoplasms which show morphologic features of both follicular and C-cell differentiation⁴¹. The dual differentiation has also been noted in their metastatic sites. These neoplasms must be distinguished from the follicular variant of medullary carcinoma and from medullary carcinoma with entrapped normal follicles. Thus, WHO is very strict in defining them as “tumors showing both the morphologic features of medullary carcinoma together with immunoreactivity for calcitonin and the morphologic features of follicular carcinoma together with immunoreactivity for thyroglobulin”⁴².

Whether these tumors represent collision tumors or arise from a stem cell capable of dual differentiation into follicular and C-cell elements is the subject of several excellent reports in the recent literature^{3,43,44}.

A.3. CYTOPLASMIC CHANGES IN THYROID TUMORS

A.3.1. Tumors with oncocyctic features: Oncocytes (oxyphilic cells, “Hürthle cells”) are derived from follicular epithelium, characterized morphologically by large size, distinct cell borders and abundant granular acidophilic cytoplasm, large nucleus and prominent nucleolus. The cytoplasmic granularity is produced by an increased number of huge mitochondria. Oncocyctic thyroid tumors (oncocyctic adenoma/carcinoma) are composed exclusively or predominately of follicular cells exhibiting oncocyctic features². However, isolated cells or groups of follicular cells with oncocyctic features can be seen in other conditions such as radiated thyroids, aging thyroids, nodular goiter, “nonspecific” chronic thyroiditis or Hashimoto’s thyroiditis and Graves’ disease. In addition, several neoplasms of the thyroid (oncocyctic papillary neoplasms, Warthin-like tumor of the thyroid, tall cell variant of papillary carcinoma) exhibit oncocyctic features^{9,45}.

A.3.2. Tumors with clear cell features: Clear cell changes can occur in any of the major histologic types of benign and malignant thyroid neoplasms. They have also been observed in nodular hyperplasia and in Hashimoto’s thyroiditis². The clearing of the cytoplasm may be the consequence of intracytoplasmic accumulation of vesicles (of mitochondrial or other origin: Hürthle cell tumors, follicular tumors), glycogen (papillary




Figure 1. Histology of Thyroid Tumors. **A.** Follicular adenoma: note the sharp separation of a follicular tumor from the surrounding tissue by a uniform fibrous capsule. **B.** Follicular carcinoma with capsular penetration. **C.** Papillary carcinoma metastatic to a lymph node: typical appearance of papillary carcinoma with complex and branching papillae. **D.** Higher magnification showing optical clear, overlapping and grooved (arrow) nuclei. **E.** Tall cell variant papillary carcinoma, lined by tall cells (arrow). **F.** Undifferentiated carcinoma with elongated tumor cells. **G.** Medullary carcinoma. **H.** Papillary carcinoma with clear cell changes: typical intranuclear inclusion (inset).

carcinoma) (Figure 1H), lipid (undifferentiated carcinoma), thyroglobulin and “mucin”².

A.3.3. Tumors with squamous features: Squamous cells in the thyroid can originate from a remnant of the thyroglossal duct or ultimobranchial body or may be the result of squamous metaplasia in Hashimoto’s thyroiditis, papillary carcinoma or other conditions⁹. Focal or extensive squamous differentiation has been described in papillary carcinoma, undifferentiated carcinoma, follicular neoplasms and medullary carcinoma².

A.3.4. Tumors with mucinous features: Mucosubstances have been detected in several thyroid tumors, either in the cytoplasm of the tumor cells or extracellularly^{46,47}. Primary thyroid tumors that have been found to contain mucin include signet ring follicular adenoma, mucoepidermoid carcinoma and sclerosing mucoepidermoid carcinoma with eosinophilia, papillary, undifferentiated and medullary carcinoma².

A.4. THYROID SARCOMAS

Sarcomas arising in the thyroid are extremely rare. Various microscopic types have been reported in the form of isolated case reports, including fibrosarcoma⁴⁸, liposarcoma⁴⁹, leiomyosarcoma⁵⁰, chondrosarcoma⁵¹, osteosarcoma^{52,53} and malignant schwannoma⁵⁴.

It is likely that most thyroid neoplasms resembling sarcomas are examples of undifferentiated (sarcomatoid) carcinomas. In addition, cartilage and bone production in association with benign and malignant thyroid lesions have been observed^{39,55}. However, the distinction between true thyroid sarcomas and sarcoma-like undifferentiated carcinomas is of little importance since the natural history and response to therapy of both entities do not differ significantly. They occur in elderly patients, are rapidly growing and are uniformly fatal⁹. The sarcoma that apparently does arise in the thyroid is angiosarcoma. It occurs predominately in Alpine regions of central Europe where it typically arises in a gland with multinodular goiter⁵⁶. Although several investigators have suggested that this entity actually represents a vascular variant of undifferentiated carcinoma, some of these tumors exhibit anastomosing vascular channels, Wiebel-Palade bodies ultrastructurally, immunoreactivity for factor-VIII related antigen and other factors consistent with endothelial differentiation⁵⁷.

A.5. MALIGNANT LYMPHOMAS

Primary non-Hodgkin lymphomas of the thyroid are now considered to be tumors of mucosa-associated lymphoid tissue (MALT)¹⁵. They constitute about 8% of all thyroid malignancies². Primary thyroid lymphomas have a B cell phenotype and are highly associated with lymphocytic or Hashimoto’s thyroiditis^{2,15}. Thyroid malignant lymphomas are most common in adult or elderly women, clinically presented in the form of an enlarged thyroid, leading to symptoms of tracheal or laryngeal compression when extended outside the gland^{2,9}. Most patients are euthyroid⁵⁸. Since MALT lymphomas characteristically metastasize to sites that contain similar tissue, it is not uncommon to see a lymphoma of the thyroid with concomitant involvement of the gastrointestinal tract^{30,59}.

Other primary lymphoid tumors include plasmacytoma and Hodgkin lymphoma².

A.6. SECONDARY TUMORS OF THE THYROID

Although any malignant tumor can metastasize to the thyroid gland, the latter is an infrequent site of tumor metastases. Direct extension into the thyroid may occur in carcinomas of the pharynx, larynx, trachea and esophagus^{2,9}. Most of these neoplasms are of squamous cell type. Retrograde lymphatic spread into the thyroid, although unusual, has been reported, with breast carcinoma being the most frequent⁹. Hematogenous metastases to the thyroid, particularly of malignant melanoma, lung, gastrointestinal, breast and renal cell carcinomas are commonly encountered at autopsy series^{2,9}. Rare sources of primary tumors, such as choriocarcinoma, malignant phylloides tumor and osteosarcoma, have also been reported⁶⁰. Some metastases are found in preexisting thyroid lesions, such as breast carcinoma into papillary carcinoma and lung and renal cell carcinoma into follicular adenoma^{2,61-63}. Particularly diagnostically challenging are metastases of unknown origin. Of these the most common are renal cell carcinoma, large bowel adenocarcinoma and malignant melanoma⁹.

Metastatic disease to the thyroid may present a diagnostic problem for the following reasons: a) Many cases are asymptomatic and too small in size to be detected clinically; b) The primary site is difficult to identify histologically, in small biopsy samples (FNA), since many metastatic lesions are poorly or moder-

ately differentiated (and sometimes undifferentiated) carcinomas; c) Metastases could be manifested long after the detection of a primary tumor (as long as 26 years); d) Many clinically detected lesions are solitary rather than multiple^{60,64}.

B. MOLECULAR MARKERS OF THYROID TUMORS

Several types of oncogene alterations have been described as possible mechanism(s) for thyroid tumorigenesis. Whether these alterations can serve as markers, predicting the biological behavior of thyroid tumors or confirming unclear diagnoses is a matter of debate. For a comprehensive review on molecular abnormalities involved in thyroid tumorigenesis see Sagev et al⁶⁵.

B.1. RAS Oncogene

RAS oncogenes (K-ras, H-ras, N-ras) activation has been identified in tumors originating from the follicular epithelium of the thyroid gland. Point mutations in ras oncogenes are more common in follicular adenoma and carcinoma than in papillary carcinoma as well as in tumors from iodide-deficient areas^{66,67}. Some studies suggest that ras activation is an early event in thyroid carcinogenesis while others indicate an association between ras mutations and tumor progression^{68,69}.

B.2. RET Oncogene

The RET (rearranged during transfection) oncogene encodes two isoforms of a transmembrane tyrosine-kinase receptor, which is involved in the development of the neural crest and kidney⁷⁰. A common genetic alteration in thyroid tumors is the rearrangements of the RET oncogene leading to the so-called RET/PTC (for papillary thyroid carcinoma) oncogene⁷¹. Experimental studies have indicated that the RET/PTC oncogene is specifically involved in the pathogenesis of thyroid tumors with morphologic features of papillary carcinomas, while a high prevalence of RET/PTC rearrangements have been reported in radiation-induced papillary carcinoma, especially in children affected in the Chernobyl reactor accident⁷⁰⁻⁷³. It is of interest that spontaneous RET mutations are also associated with familial and sporadic medullary carcinomas⁶⁵.

Recent studies showed that RET/PTC was more

frequently expressed in papillary microcarcinomas than in clinically manifest tumors, and poorly differentiated thyroid cancer has a low prevalence in RET activation^{36,74}. It therefore appears that rearrangement of RET/PTC is an early event in papillary thyroid carcinoma development and is less important in tumor progression.

B.3. p53

The p53 tumor suppressor gene is the most frequent mutated gene in human cancer. With regard to the thyroid, p53 gene mutations are rarely observed in differentiated tumors and are more commonly found in poorly differentiated and anaplastic carcinomas^{75,76}. The high p53 protein expression in undifferentiated carcinomas, compared to papillary carcinomas, and the absence of mutations in the residual papillary component suggest that p53 genetic alterations are late events in the sequence of thyroid carcinogenesis and could be linked to their reported worse prognosis^{77,78}.

B.4. MET

c-MET oncogene encodes a tyrosine kinase acting as the receptor for hepatocyte growth factor/scatter factor (HGF/SF), a powerful mitogen for epithelial cells, including thyroid follicular cells^{65,79}. MET overexpression is associated with the papillary thyroid carcinoma phenotype, particularly its aggressive forms, being negative in medullary carcinomas and low or absent in poorly differentiated tumors^{79,80}. Data on the significance of MET overexpression in thyroid tumors are inconsistent. Some studies found MET overactivity to be associated with advanced tumor stage and histologic variants with poor prognosis, while others showed a relationship between negative/low expression and vascular invasion and distant metastases^{79,81}.

C. CONCLUSIONS

Thyroid tumors can originate from follicular epithelium, from parafollicular or C cells or from nonepithelial stromal components. The traditional classification of thyroid cancer as well differentiated carcinomas, characterized by relatively good prognosis, or poorly differentiated carcinomas associated with aggressive behavior, metastases and death, is no longer applicable since certain morphologic variants of papillary carcinoma are associated with poor prognosis.

The hyalinizing trabecular adenoma of the thyroid remains a controversial entity, while the concept of poorly differentiated carcinoma still constitutes a complicated issue. The practical importance of the various cytoplasmic changes seen in thyroid lesions resides on differential diagnosis rather than their biological behavior. Several types of molecular alterations occurring in thyroid tumors are under investigation in order to enhance our understanding of the possible mechanisms of thyroid tumorigenesis. The clinical significance of these studies remains to be defined.

REFERENCES

- Hedinger C, Williams ED, Sobin LH, 1989 The WHO histological classification of thyroid tumors: A commentary on the second edition. *Cancer* 63: 908-911.
- Rosai J, Carcangiu ML, DeLellis RA, 1992 Tumors of the Thyroid Gland. Atlas of Tumor Pathology, Armed Forces Institute of Pathology, Washington, D.C.
- Albores-Saavedra J, Gorraez-de-la-Mora T, Torre-Rendon F, Gould E, 1990 Mixed medullary-papillary carcinoma of the thyroid: A previously unrecognized variant of thyroid carcinoma. *Hum Pathol* 21: 1151-1155.
- Cheung CC, Boerner SL, MacMillan CM, Ramyar L, Asa SL, 2000 Hyalinizing trabecular tumor of the thyroid: A variant of papillary carcinoma proved by molecular genetics. *Am J Surg Pathol* 24: 1622-1626.
- Papotti M, Volante M, Giuliano A, et al, 2000 RET/PTC activation in hyalinizing trabecular tumors of the thyroid. *Am J Surg Pathol* 24: 1615-1621.
- Shikama Y, Osawa T, Yagihashi N, Kurotaki H, Yagihashi S, 2003 Neuroendocrine differentiation in hyalinizing trabecular tumors of the thyroid. *Virchows Archiv* 443: 792-796.
- Lloyd RV, 2002 Hyalinizing trabecular tumors of the thyroid: a variant of papillary carcinoma? *Adv Anatom Pathol* 9: 7-11.
- Franssila KO, Ackerman LV, Brown CL, Hedinger CE, 1985 Follicular carcinoma. *Sem Diagn Pathol* 2: 101-122.
- LiVolsi VA 1990 Surgical Pathology of the Thyroid In: Bennington JL (ed) Major Problems in Pathology, vol. 22, WB Saunders Co, Philadelphia.
- Sobrinho-Simões M, 1995 Tumors of thyroid: A brief overview with emphasis on the most controversial issues. *Curr Diagn Pathol* 2: 15-22.
- Scopa CD, 1998 Thyroid tumors: Advantages and limitations in histopathologic diagnosis. *Archives Hellenic Medicine* 15: Suppl A: 182-185.
- Scopa CD, Peristeropoulou P, Aroukatos P, Tsamandas AC, 2001 Intraoperative diagnosis of thyroid disease. *Archives Hellenic Medicine* 18: 375-378.
- Carcangiu ML, Bianchi S, Savino D, Voynick IM, Rosai J, 1991 Follicular Hürthle cell tumors of the thyroid. *Cancer* 68: 1944-1953.
- Papotti M, Torchio B, Grassi L, Favero A, Bussolati G, 1996 Poorly differentiated oxyphilic (Hürthle cell) carcinomas of the thyroid. *Am J Surg Pathol* 20: 686-694.
- Baloch ZW, LiVolsi VA 2002 Pathology of thyroid gland In: VA LiVolsi, SL Asa (eds), *Endocrine Pathology*, Churchill Livingstone, New York, pp, 61-101.
- Chan JK, Saw D, 1986 The grooved nucleus. A useful diagnostic criterion of papillary carcinoma of the thyroid. *Am J Surg Pathol* 10: 672-679.
- Deligeorgi-Politi H, 1987 Nuclear crease as a cytodiagnostic feature of papillary thyroid carcinoma in fine-needle aspiration biopsies. *Diagn Cytopathol* 3: 307-310.
- Scopa CD, Melachrinou M, Saradopolou C, Merino MJ, 1993 The significance of the grooved nucleus in thyroid lesions. *Mod Pathol* 6: 691-694.
- Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J, 1985 Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. *Cancer* 55: 805-828.
- Rosai J, LiVolsi VA, Sobrinho-Simões M, Williams ED, 2003 Renaming papillary microcarcinoma of the thyroid gland: The Porto proposal. *Intl J Surg Pathol* 11: 249-251.
- Scopa CD, Petrohilos J, Spiliotis J, Melachrinou M, 1993 Autopsy findings in clinically normal thyroids. A study in a southwestern Greek population. *Int J Surg Pathol* 1: 25-32.
- Vickery AL, Carcangiu ML, Johannessen LV, Sobrinho-Simões M, 1985 Papillary carcinoma. *Sem Diagn Pathol* 2: 90-100.
- Harach HR, Franssila KO, Wasenius VW, 1985 Occult papillary carcinoma of the thyroid: A "normal" finding in Finland. A systematic autopsy study. *Cancer* 56: 531-538.
- LiVolsi VA, 1992 Papillary neoplasms of the thyroid. Pathologic and prognostic features. *Am J Clin Pathol* 97: 426-434.
- Sobrinho-Simões M, Soares J, Carneiro F, Limbert E, 1990 Diffuse follicular variant of papillary carcinoma of the thyroid: report of eight cases of a distinct aggressive type of thyroid tumor. *Surg Pathol* 3: 189-203.
- Albores-Saavedra J, Gould E, Vardaman C, Vuitch F, 1991 The macrofollicular variant of papillary thyroid carcinoma: A study of 17 cases. *Hum Pathol* 22: 1195-1205.
- Johnson TL, Lloyd RV, Thompson NW, Beierwaltes WH, Sisson JC, 1988 Prognostic implications of the tall cell variant of papillary thyroid carcinoma. *Am J Surg Pathol* 12: 22-27.
- Sobrinho-Simões M, Nesland JM, Johannessen JV, 1988 Columnar-cell carcinoma. Another variant of poorly differentiated carcinoma of the thyroid. *Am J Clin Pathol* 89: 264-267.
- Wenig BM, Thompson LDR, Adair CF, Shmookler B, Heffess CS, 1998 Thyroid papillary carcinoma of columnar cell type. A clinicopathologic study of 16 cases. *Cancer* 82: 740-753.
- Nishiyama RH, 2000 Overview of surgical pathology of the thyroid gland. *World J Surg* 24: 898-906.
- Baloch ZW, LiVolsi VA, 2000 Newly described tumors

- of the thyroid. *Current Diagn Pathol* 6: 151-164.
32. Volante M, Landolfi S, Chiusa L, et al, 2004 Poorly differentiated carcinomas of the thyroid with trabecular, insular and solid patterns. A clinicopathologic study of 183 patients. *Cancer* 100: 950-957.
 33. Sobrinho-Simões M, Sambade C, Fonseca E, Soares P, 2002 Poorly differentiated carcinomas of the thyroid gland. A review of the clinicopathologic features of 28 cases of a heterogeneous, clinically aggressive group of thyroid tumors. *Int J Surg Pathol* 10: 123-131.
 34. Carcangiu ML, Zampi G, Rosai J, 1984 Poorly differentiated ("insular") thyroid carcinoma. A reinterpretation of Langhans' "wuchernde Struma". *Am J Surg Pathol* 8: 655-658.
 35. Ljunberg O, Bondeson L, Bondeson A-G, 1984 Differentiated thyroid carcinoma, intermediate type: A new tumor entity with features of follicular and parafollicular cell carcinoma. *Hum Pathol* 15: 218-228.
 36. Santoro M, Papotti M, Chiappetta G, et al, 2002 RET activation and clinicopathologic features in poorly differentiated thyroid tumors. *J Clin Endocrinol Metab* 87: 370-379.
 37. Rocha AS, Soares P, Fonseca E, Cameselle-Teijeiro J, Oliveira M, Sobrinho-Simões M, 2003 E-cadherin loss rather than β -catenin alterations is a common feature of poorly differentiated thyroid carcinomas. *Histopathology* 42: 580-587.
 38. Furihata M, Ohtsuki Y, Matsumoto M, Sonobe H, Okada Y, Watanabe R, 2001 Immunohistochemical characterization of a case of insular thyroid carcinoma. *Pathology* 33: 257-261.
 39. Rosai J, Saxen EA, Woolner L, 1985 Undifferentiated and poorly differentiated carcinoma. *Sem Diagn Pathol* 2: 123-136.
 40. Albores-Saavedra J, LiVolsi VA, Williams ED, 1985 Medullary carcinoma. *Sem Diagn Pathol* 2: 137-146.
 41. Holm R, Sobrinho-Simões M, Nesland JM, Sambade C, Johannessen JV, 1987 Medullary thyroid carcinoma with thyroglobulin immunoreactivity. A special entity? *Lab Invest* 57: 258-268.
 42. Hedinger C, Williams E, Sobin L 1988 Histological typing of thyroid tumors In: World Health Organization International Histological Classification of Tumors. Springer Verlag, Berlin.
 43. Volante M, Papotti M, Roth J, et al, 1999 Mixed medullary-follicular thyroid carcinoma. Molecular evidence for a dual origin of tumor components. *Am J Pathol* 155: 1499-1509.
 44. Matias-Guiu X, 1999 Mixed medullary and follicular carcinoma of the thyroid. On the search for its histogenesis. *Am J Pathol* 155: 1413-1418.
 45. Baloch ZW, LiVolsi VA, 1999 Oncocytic lesions of the neuroendocrine system. *Sem Diagn Pathol* 16: 190-199.
 46. Mlynec ML, Richter HJ, Leder LD, 1985 Mucin in carcinomas of the thyroid. *Cancer* 56: 2647-2650.
 47. Gherardi G, 1987 Signet ring cell "mucinous" thyroid adenoma: a follicle cell tumor with abnormal accumulation of thyroglobulin and a peculiar histochemical profile. *Histopathology* 11: 317-326.
 48. Shin W-Y, Aftalion B, Hotchkiss E, Schenkman R, Berkman J, 1979 Ultrastructure of a primary fibrosarcoma of the human thyroid gland. *Cancer* 44: 584-591.
 49. Andrion A, Gaglio A, Dogliani N, Bosco E, Mazzucco G, 1991 Liposarcoma of the thyroid gland. Fine needle aspiration cytology, immunohistology and ultrastructure. *Am J Clin Pathol* 95: 675-679.
 50. Thompson LDR, Wenig BM, Adair CF, Shmookler BM, Heffess CS, 1997 Primary smooth muscle tumors of the thyroid gland. *Cancer* 79: 579-587.
 51. Tseleni-Balafouta S, Arvanitis D, Kakaviatos N, Paraskevavou H, 1988 Primary myxoid chondrosarcoma of the thyroid gland. *Arch Pathol Lab Med* 112: 94-96.
 52. Ohbu M, Kameya T, Wada C, 1989 Primary osteogenic sarcoma of the thyroid gland. A case report. *Surg Pathol* 2: 67-72.
 53. Nitzsche EU, Seeger LL, Klosa B, Freudenberg N, Moser EA, 1992 Primary osteosarcoma of the thyroid gland. *J Nucl Med* 33: 1399-1401.
 54. Naruse T, Koike A, Suzumura K, Matsumoto K, Inamura Y, Saiguse J, 1991 Malignant "triton" tumor in the thyroid-A case report. *Jpn J Surg* 21: 466-470.
 55. Tzanakakis GN, Scopa CD, Vezeridis MP, Vagenakis A, 1989 Ectopic bone in multinodular goiter. *Rhode Island Medical Journal* 72: 171-172.
 56. Hedinger CE, 1981 Geographic pathology of the thyroid diseases. *Pathol Res Pract* 171: 285-292.
 57. Tanda F, Massarelli G, Bosincu L, Cossu U, 1988 Angiosarcoma of the thyroid: a light, electron microscopic and immunological study. *Hum Pathol* 19: 742-745.
 58. Devine RM, Edis AJ, Banks PM, 1981 Primary lymphoma of the thyroid: a review of the Mayo Clinic experience through 1978. *World J Surg* 5: 33-38.
 59. Akester KE, Somasundaram N, Diaz-Cano S, Grossman AB, 2003 Cancer in the thyroid is not always thyroid cancer. *Hormones* 2: 250-255.
 60. Lam KY, Lo CY, 1998 Metastatic tumors of the thyroid gland. *Arch Pathol Lab Med* 122: 37-41.
 61. Mizukami Y, Saito K, Nonomura A, 1990 Lung carcinoma metastatic to microfollicular adenoma of the thyroid. A case report. *Acta Pathol Jpn* 40: 602-608.
 62. Ro JY, Guerrieri C, al-Naggar AK, Ordonez NG, Sorge JG, Ayala AG, 1994 Carcinomas metastatic to follicular adenoma of the thyroid gland. Report of two cases. *Arch Pathol Lab Med* 118: 551-556.
 63. Baloch BW, LiVolsi VA, 1999 Tumor-to-tumor metastasis to follicular variant of papillary carcinoma of thyroid. *Arch Pathol Lab Med* 123: 703-706.
 64. Bult P, Verwiel JMM, Wobbes T, Kooy-Smits MM, Biert J, Holland R, 2000 Malignant adenomyoepithelioma of the breast with metastasis in the thyroid gland 12 years after excision of the primary tumor. *Virchows Arch* 436: 158-166.
 65. Segev DL, Umbridht C, Zeiger MA, 2003 Molecular pathogenesis of thyroid cancer. *Surg Oncol* 12: 69-90.
 66. Manenti G, Pilotti FC, Re FC Della Porta G, Pierotti MA, 1994 Selective activation of ras oncogenes in follicular and

- undifferentiated carcinomas. *Eur J Cancer* 30: 987-993.
67. Shi YF, Zou MJ, Schidt H, 1991 High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. *Cancer Res* 51:2690-2693
 68. Lemoine NR, Mayall ES, Wyllie FS, 1989 High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. *Oncogene* 4: 159-164.
 69. Basolo F, Pisaturo F, Pollina LE, 2000 N-ras mutation in poorly differentiated thyroid carcinomas; correlation with bone metastases and inverse correlation to thyroglobulin expression. *Thyroid* 10: 19-23.
 70. Tallini G, Asa SL, 2001 RET oncogene activation in papillary thyroid carcinoma. *Adv Anatom Pathol* 8: 345-354.
 71. Santoro M, Carlomagno F, Hay ID, et al, 1992 RET oncogene activation in human thyroid neoplasms is restricted to the papillary carcinoma subtype. *J Clin Invest* 89: 1517-1522.
 72. Bounacer A, Wicker R, Baillou B, et al, 1997 High prevalence of activating ret proto-oncogene rearrangements in thyroid tumors from patients who had received external radiation. *Oncogene* 15: 1263-1273.
 73. Nikiforov YE, Rowland JM, Bove KE, Mouferte-Munoz H, Fagin JA, 1997 Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. *Cancer Res* 57: 1690-1694.
 74. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL, 1998 Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. *J Clin Endocrinol Metab* 83: 4116-4122.
 75. Ito T, Seyama T, Mizuno T, et al, 1992 Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. *Cancer Res* 52: 1369-1371.
 76. Nakamura T, Yana I, Kobayashi T, et al, 1992 p53 gene mutation associated with anaplastic transformation of human thyroid carcinomas. *J Jpn Cancer Res* 83: 1293-1298.
 77. Batistatou A, Zolota V, Tiniakos DG, Scopa CD, 1999 p53, bcl-2 and bax expression in thyroid carcinomas. *Virchows Archiv* 435: A221.
 78. Fagin JA, 1995 Tumor suppressor genes in human thyroid neoplasms: p53 mutations are associated with undifferentiated thyroid cancers. *J Endocrinol Invest* 18: 140-142.
 79. Di Renzo MF, Olivero M, Serini G, et al, 1995 Overexpression of the c-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. *J Endocrinol Invest* 18: 134-139.
 80. Ruco LP, Ranalli T, Marzullo A, et al, 1996 Expression of Met protein in thyroid tumors. *J Pathol* 180: 266-270.
 81. Belfiore A, Gangemi P, Constantino A, et al, 1997 Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinoma with high risk of distant metastases. *J Clin Endocrinol Metab* 82: 2322-2328.